TCP-600 Supplementation and Performance Response in Professional Football Players

NCT07710547 | Not Yet Recruiting

• 1 other identifier: VIZJA-TCP600-RESP-2026 (28)
• Study Type: interventional
• Target: 65
• Locations: 1 country
• Sites: 3

Brief Summary

This study will examine whether a 28-day supplementation protocol containing taurine, caffeine, and phosphatidylserine can help professional male football players maintain physical performance, cognitive function, recovery-related readiness, and selected football-specific perceptual-cognitive performance. Participants will be randomly assigned to receive either placebo or a phosphatidylserine-containing multi-ingredient supplement. Before and after the supplementation period, players will complete non-invasive assessments such as sprint testing, reaction-time testing, heart rate variability monitoring, wellness/readiness questionnaires, mental-fatigue measures, and selected football-specific perceptual-cognitive tasks where available. The study is designed as an external validation and extension of responder profiles derived from previous randomized controlled trials. Data from previous trials and this validation cohort will be used to examine whether baseline physical, cognitive, autonomic, fatigue-related, recovery-related, or perceptual-cognitive characteristics can predict which players are most likely to benefit from phosphatidylserine-containing multi-ingredient supplementation.

Conditions

Athletic Performance; Cognitive Fatigue; Exercise Recovery; Football-Specific Performance; Perceptual-cognitive Performance

Keywords

Phosphatidylserine; Taurine; Caffeine; Football players; Soccer; Responder analysis; Heart rate variability; LnRMSSD; Reaction time; Mental fatigue; Sports nutrition; Individual responsiveness; Decision-making; Perceptual-cognitive performance; Recovery

Outcome Measures

Primary Outcomes (1)

• Proportion of Participants Classified as Multidimensional Responders After 28 Days

  Proportion of participants classified as multidimensional responders after 28 days of supplementation. A multidimensional responder will be defined as a participant meeting the predefined response criterion in at least two of four domains: physical performance/fatigue resistance, cognitive fatigue-related performance, recovery/readiness, and football-specific perceptual-cognitive performance. The outcome will be reported as the percentage of participants classified as multidimensional responders in each group. Unit of Measure: percentage of participants

  Baseline to post-intervention after 28 days of supplementation

Secondary Outcomes (11)

• Change in 30 m Sprint Time

  Baseline to post-intervention after 28 days of supplementation

• Change in Cognitive Fatigue Task Reaction Time

  Baseline to post-intervention after 28 days of supplementation

• Change in Perceived Mental Fatigue VAS Score

  Baseline to post-intervention after 28 days of supplementation.

• Change in Final 3-Day Mean LnRMSSD

  Baseline monitoring period to final 3 days of supplementation.

• Change in Readiness-to-Train Rating Scale Score

  Baseline monitoring period to final 3 days of supplementation.

Study Arms (3)

Placebo

PLACEBO COMPARATOR

Participants assigned to this arm will receive placebo capsules for 28 consecutive days. Placebo capsules will be matched to the active supplement in appearance, number, packaging, and administration schedule.

Other: Placebo

Taurine + Caffeine

ACTIVE COMPARATOR

Participants assigned to this arm will receive taurine 1500 mg/day and anhydrous caffeine 200 mg/day, administered orally once daily for 28 consecutive days. Matching placebo capsules will be used to maintain the same total number and appearance of capsules across study arms.

Dietary Supplement: Taurine; Dietary Supplement: Caffeine

Taurine + Caffeine + Phosphatidylserine

EXPERIMENTAL

Participants assigned to this arm will receive a multi-ingredient supplementation protocol containing taurine 1500 mg/day, anhydrous caffeine 200 mg/day, and phosphatidylserine 600 mg/day, administered orally once daily for 28 consecutive days. This intervention is referred to as the TCP-600 protocol.

Dietary Supplement: Taurine; Dietary Supplement: Caffeine; Dietary Supplement: Phosphatidylserine

Interventions

Placebo OTHER

Matching placebo capsules administered orally once daily for 28 consecutive days. The placebo was matched to the active supplements in appearance, number, packaging, and administration schedule.

Placebo

Taurine DIETARY_SUPPLEMENT

Taurine 1500 mg/day administered orally once daily in capsules for 28 consecutive days.

Taurine + Caffeine; Taurine + Caffeine + Phosphatidylserine

Caffeine DIETARY_SUPPLEMENT

Anhydrous caffeine 200 mg/day administered orally once daily in capsules for 28 consecutive days.

Taurine + Caffeine; Taurine + Caffeine + Phosphatidylserine

Phosphatidylserine DIETARY_SUPPLEMENT

Phosphatidylserine 600 mg/day administered orally once daily in capsules for 28 consecutive days.

Taurine + Caffeine + Phosphatidylserine

Eligibility Criteria

• Age: 18 Years - 36 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male professional or highly trained football players aged 18-36 years.
• Regular participation in structured football training and team activities.
• Minimum of 5 years of structured football training experience.
• Regular involvement in club training during the study period.
• Medical clearance or no known contraindications to high-intensity exercise testing.
• Ability to complete sprint, reaction-time, cognitive-fatigue, heart-rate-variability, wellness/readiness, and selected football-specific perceptual-cognitive assessments where available.
• Willingness to maintain usual diet and training habits during the study period.
• Willingness to avoid additional ergogenic supplements outside the study protocol during the intervention.
• Willingness to follow caffeine restrictions before testing sessions.
• Written informed consent provided before participation.

You may not qualify if:

• Current musculoskeletal injury or illness preventing full participation in training or testing.
• Musculoskeletal injury within the previous 3 months that may affect sprint, football-specific performance, or perceptual-cognitive testing.
• Cardiovascular, metabolic, neurological, psychiatric, or other chronic disease that may affect safety or study outcomes.
• Diagnosed sleep disorder.
• Use of medication affecting heart rate, autonomic nervous system function, sleep, cognition, or exercise performance.
• Known hypersensitivity or intolerance to caffeine, taurine, phosphatidylserine, or any supplement ingredient.
• Regular use of ergogenic supplements that cannot be discontinued before and during the study period.
• Smoking or regular use of nicotine products.
• Participation in another interventional study during the same period.
• Inability to comply with supplementation, monitoring, or testing procedures.
• Failure to provide written informed consent.

Sponsors & Collaborators

• Vizja University in Warsaw: lead

Study Sites (3)

Professional Football Training Center

Krakow, Poland

Location

Professional Football Training Center

Lodz, 01-043, Poland

Location

Professional Football Training Center

Warsaw, 01-043, Poland

Location

MeSH Terms

Conditions

Mental Fatigue

Interventions

Taurine; Caffeine; Phosphatidylserines

Condition Hierarchy (Ancestors)

Fatigue; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Behavioral Symptoms; Behavior

Intervention Hierarchy (Ancestors)

Alkanesulfonic Acids; Alkanes; Hydrocarbons, Acyclic; Hydrocarbons; Organic Chemicals; Sulfonic Acids; Sulfur Acids; Sulfur Compounds; Xanthines; Alkaloids; Heterocyclic Compounds; Purinones; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Glycerophospholipids; Phosphatidic Acids; Glycerophosphates; Phospholipids; Membrane Lipids; Lipids

Central Study Contacts

Krzysztof Maciej Mizera, PhD

CONTACT

+48508356718; krzysztofmizera@o2.pl

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: Participants, investigators, supplementation supervisors, outcome assessors, coaches rating tactical performance, and the statistician will be blinded to group allocation. Placebo and active supplement capsules will be identical in appearance, number, packaging, and administration schedule. Supplement packs will be coded so that group allocation cannot be identified by participants, club staff, investigators, or outcome assessors. The randomization code will be kept by an independent person not involved in recruitment, supplement distribution, outcome assessment, or statistical analysis and will be revealed only after completion of data collection and primary analyses.
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor / Principal Investigator

Model Details: Participants will be randomly assigned in a 1:1:1 ratio to placebo, taurine plus caffeine, or taurine plus caffeine plus phosphatidylserine 600 mg/day for 28 days. The study will use a randomized, double-blind, placebo- and active-controlled, parallel-group design. This validation cohort will be used to test and extend predefined multidimensional responder profiles in professional football players, with particular focus on identifying players most likely to benefit from the addition of phosphatidylserine to taurine-caffeine supplementation.

Study Record Dates

• First Submitted: July 4, 2026
• First Posted: July 17, 2026
• Study Start: August 1, 2026
• Primary Completion: August 1, 2026
• Study Completion (Estimated): September 1, 2026
• Last Updated: July 21, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

PL (3)